CMPX - Compass Therapeutics, Inc.
IEX Last Trade
1.525
-0.015 -0.984%
Share volume: 2,490
Last Updated: Thu 26 Dec 2024 08:30:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$1.54
-0.02
-0.97%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-0.66%
1 Month
-0.66%
3 Months
-17.13%
6 Months
41.51%
1 Year
-5.66%
2 Year
-72.27%
Key data
Stock price
$1.52
DAY RANGE
$1.44 - $1.54
52 WEEK RANGE
$0.86 - $2.34
52 WEEK CHANGE
$0.67
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Thomas J. Schuetz
Region: US
Website: compasstherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: compasstherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trials for colorectal and ovarian cancer.
Recent news